RMD has rallied sharply this week following upgrades from JP Morgan, they raised the stock to a buy with a price target of ~$35, around 7% above yesterday’s close. In line with our short-term positive outlook towards growth/tech stocks healthcare should perform well and our ideal target for RMD is in excess of $36, above its 2022 high.
- We have remained patient with our RMD position and have no plans to cut & run now some buying has emerged.
MM remains long and bullish RMD
Add To Hit List
